Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Inclusion Criteria:

• Informed consent obtained

• Subjects diagnosed with type 2 diabetes and treated with either diet and exercisealone, metformin, sulphonylurea, glitazone as single agent therapy or a combination ofthe previously mentioned compounds

• HbA1c 7.0-10.0% (both inclusive)

• Body Mass Index (BMI) at least 27.0 kg/m^2

• Stable body weight

• Preceding failed dietary effort

Exclusion Criteria:

• Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidylpeptidase-4 (DPP-4) inhibitors or insulin within the last 3 months

• Known proliferative retinopathy or maculopathy

• History of acute or chronic pancreatitis

• Obesity induced by drug treatment

• Use of approved weight lowering pharmacotherapy

• Previous surgical treatment of obesity

• History of major depressive disorder or suicide attempt

• Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/ordiastolic blood pressure above or equal to 100 mmHg)

• Screening calcitonin of 50 ng/L or above

• Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familialmedullary thyroid carcinoma (FMTC)

• Personal history of non-familial medullary thyroid carcinoma